"A booming economy has increased disposable incomes and raised living standards. As a result, demand for pharmaceutical products has risen as Chinese people have climbed up the economic ladder.

"These trends have been accompanied by greater participation in the State Basic Medical Insurance System and increased government spending on health care.

"AOB has benefited from a general preference in China for TCMs over synthetically manufactured alternatives. Complementary acquisitions have also contributed to the company's growth.

"Total revenues and net income over the past three years climbed fivefold to $160 million and $43.3 million in 2007, respectively. Q1 2008 net revenues jumped 50.7% from a year ago to $38.8 million.

"Strong OTC sales more than offset slower growth in the prescription business and falling PBN points to 67.82% due to a shift in the sales mix and higher expenses associated with the integration of an acquisition.

"Investment risks include the planned issuance of $115 million of convertible bonds,which could dilute future earnings; and the sometimes capricious nature of Chinese laws and regulations.

"However, we are focused more on potential growth. Organic sales should rise 30% in 2008. Total sales growth should exceed 50%. Net income is expected to climb at least 43%.

"The company has set aside $16.4 million to fund acquisitions that are already in the pipeline. These expected acquisitions should help AOB build scale and expand market share in China's fragmented pharmaceutical and nutraceutical markets."

Steven Halpern's TheStockAdvisors.com offers a daily look at the latest market commentary and favorite stock picks and investment ideas from the nation's leading financial newsletter advisors.